Dongyoon Kim

Mr. Dongyoon Kim

Seoul National University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2024 in Nano Letters
Verified
Journal Article
Closed access
EHEmily L. Han
Emily L. Han
STSophia Tang
Sophia Tang
DKDongyoon Kim
Dongyoon Kim
AMAmanda M. Murray
Amanda M. Murray
KSKelsey L. Swingle
Kelsey L. Swingle
MMMichael Mitchell
Michael Mitchell

19 December 2024 in ACS Nano
Verified
Journal Article
Closed access
YHYoon-Ho Hwang
Yoon-Ho Hwang
SSSarah J. Shepherd
Sarah J. Shepherd
DKDongyoon Kim
Dongyoon Kim
AMAlvin J. Mukalel
Alvin J. Mukalel
MMMichael Mitchell
Michael Mitchell
DLDaeyeon Lee
Daeyeon Lee

18 December 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DKDongyoon Kim
Dongyoon Kim
QLQuoc-Viet Le
Quoc-Viet Le
Yina WuYina Wu
Yina Wu
JPJinwon Park
Jinwon Park
YOYu-Kyoung Oh
Yu-Kyoung Oh
Genome-editing technology has emerged as a potential tool for treating incurable diseases for which few therapeutic modalities are available. In particular, discovery of the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas system together with the design of single-guide RNAs (sgRNAs) has sparked medical applications of genome editing. Despite the great promise of the CRISPR/Cas system, its clinical application is limited, in large part, by the lack of adequate delivery technology. To overcome this limitation, researchers have investigated various systems, including viral and nonviral vectors, for delivery of CRISPR/Cas and sgRNA into cells. Among nonviral delivery systems that have been studied are nanovesicles based on lipids, polymers, peptides, and extracellular vesicles. These nanovesicles have been designed to increase the delivery of CRISPR/Cas and sgRNA through endosome escape or using various stimuli such as light, pH, and environmental features. This review covers the latest research trends in nonviral, nanovesicle-based delivery systems that are being applied to genome-editing technology and suggests directions for future progress.

22 August 2022 in Asian Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
HJHyemin Ju
Hyemin Ju
DKDongyoon Kim
Dongyoon Kim
YOYu-Kyoung Oh
Yu-Kyoung Oh
Metabolic engineering of the tumor microenvironment has emerged as a new strategy. Lactate dehydrogenase A (LDHA) is a prominent target for metabolic engineering. Here, we designed a cationic lipid nanoparticle formulation for LDHA gene editing. The plasmid DNA delivery efficiency of our lipid nanoparticle formulations was screened by testing the fluorescence of lipid nanoparticles complexed to plasmid DNA encoding green fluorescence protein (GFP). The delivery efficiency was affected by the ratios of three components: a cationic lipid, cholesterol or its derivative, and a fusogenic lipid. The lipid nanoparticle designated formulation F3 was complexed to plasmid DNA co-encoding CRISPR-associated protein 9 and LDHA-specific sgRNA, yielding the lipoplex, pCas9-sgLDHA/F3. The lipoplex including GFP-encoding plasmid DNA provided gene editing in HeLa-GFP cells. Treatment of B16F10 tumor cells with pCas9-sgLDHA/F3 yielded editing of the LDHA gene and increased the pH of the culture medium. pCas9-sgLDHA/F3 treatment activated the interferon-gamma and granzyme production of T cells in culture. In vivo, combining pCas9-sgLDHA/F3 with immune checkpoint-inhibiting anti-PD-L1 antibody provided a synergistic antitumor effect and prolonged the survival of tumor model mice. This study suggests that combining metabolic engineering of the tumor microenvironment with immune checkpoint inhibition could be a valuable antitumor strategy.

3 April 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DKDongyoon Kim
Dongyoon Kim
Yina WuYina Wu
Yina Wu
Gayong ShimGayong Shim
Gayong Shim
YOYu-Kyoung Oh
Yu-Kyoung Oh
Lymphatic delivery of a vaccine can be achieved using a dendritic cell (DC)-targeted delivery system that can cause DC to migrate to lymph nodes upon activation by an adjuvant. Here, we designed a mannose-modified cationic lipid nanoparticle (M-NP) to deliver the nucleic acid adjuvant, polyinosinic:polycytidylic acid (PIC). PIC-loaded M-NP (PIC/M-NP) showed stable lipoplexes regardless of the ligand ratio and negligible cytotoxicity in bone marrow-derived DC. DC uptake of PIC/M-NP was demonstrated, and an increased mannose ligand ratio improved DC uptake efficiency. PIC/M-NP significantly promoted the maturation of bone marrow-derived DC, and local injection of PIC/M-NP to mice facilitated lymphatic delivery and activation (upon NP uptake) of DC. Our results support the potential of PIC/M-NP in delivering a nucleic acid adjuvant for the vaccination of antigens.

20 November 2020 in Biomedicines
Verified
Journal Article
Open access
PDF file
JBjunho byun
junho byun
DKDongyoon Kim
Dongyoon Kim
JCJae Hyun Choi
Jae Hyun Choi
Gayong ShimGayong Shim
Gayong Shim
YOYu-Kyoung Oh
Yu-Kyoung Oh
Photoresponsive nanomaterials have recently received great attention in the field of cancer therapy. Here, we report a photosensitizer-trapped gold nanocluster that can facilitate dual light-responsive cancer therapy. We utilized methylene blue (MB) as a model photosensitizer, gold nanocluster as a model photothermal agent, and a polymerized DNA as the backbone of the nanocluster. We synthesized MB-intercalated gold DNA nanocluster (GMDN) via reduction and clustering of gold ions on a template consisting of MB-intercalated long DNA. Upon GMDN treatment, cancer cells revealed clear cellular uptake of MB and gold clusters; following dual light irradiation (660 nm/808 nm), the cells showed reactive oxygen species generation and increased temperature. Significantly higher cancer cell death was observed in cells treated with GMDN and dual irradiation compared with non-irradiated or single light-irradiated cells. Mice systemically injected with GMDN showed enhanced tumor accumulation compared to that of free MB and exhibited increased temperature upon near infrared irradiation of the tumor site. Tumor growth was almost completely inhibited in GMDN-treated tumor-bearing mice after dual light irradiation, and the survival rate of this group was 100% over more than 60 days. These findings suggest that GMDN could potentially function as an effective phototherapeutic for the treatment of cancer disease.